We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis has received additional European Union (EU) approvals for Glivec (imatinib) to treat patients with a rapidly progressive form of leukemia as well as a hard-to-treat solid cancer tumor.
Nektar Therapeutics has announced that its Amphotericin B Inhalation Powder (ABIP) product has been granted orphan drug designation by the European Commission for the prevention of pulmonary fungal infections in at-risk patients.
Nastech Pharmaceutical has announced the start of a Phase I pharmacokinetic study designed to evaluate the safety, bioavailability and glucose response of Nastech's rapid-acting intranasal insulin formulation.
Aastrom Biosciences has reported additional interim results from patients enrolled in its U.S. Phase I/II trial evaluating tissue-repair cells (TRCs) in the treatment of recalcitrant long-bone non-union fractures.
SciClone Pharmaceuticals and Sigma-Tau have reported interim data showing that the addition of Zadaxin to standard dacarbazine (DTIC) chemotherapy, with or without interferon alpha, in patients with Stage IV malignant melanoma achieved double the overall tumor response compared with the control group.
Genmab announced it has initiated a Phase III trial with HuMax- EGFr (zalutumumab) to treat patients with head and neck cancer that is considered incurable with standard treatment.